AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis.
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2015
At a glance
- Drugs AGN 229666 (Primary)
- Indications Allergic conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 26 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2014 New trial record